DiscoveryProbe™ FDA-approved Drug Library: High-Throughput Screening for Target Identification

Executive Summary: The DiscoveryProbe™ FDA-approved Drug Library (L1021) consists of 2,320 bioactive compounds, each approved by major regulatory agencies such as the FDA, EMA, HMA, CFDA, and PMDA [Product Page]. Compounds are pre-dissolved at 10 mM in DMSO, supplied in formats suitable for automated high-throughput screening (HTS) and high-content screening (HCS) workflows. The collection covers a comprehensive range of pharmacological mechanisms including enzyme inhibition, receptor modulation, and signal pathway regulation. Rigorous benchmarks demonstrate its utility for rapid drug repositioning and novel target identification, especially in oncology and antiviral discovery (Tseligka et al., 2023). Its stability and regulatory diversity make it a foundational resource for translational and preclinical research.

Biological Rationale

The efficient identification of pharmacologically active compounds is a prerequisite for modern drug discovery. FDA-approved compound libraries enable researchers to explore already clinically validated molecules for new therapeutic purposes, streamlining the translation from bench to bedside [ApexBio]. Repurposing approved drugs reduces development timelines and costs, as safety and pharmacokinetic data are established [Internal: High-Throughput Compound Panel]. For example, repositioning strategies using these libraries have led to the identification of new antiviral and anticancer candidates (Tseligka et al., 2023). This approach is especially pertinent in rapidly evolving disease contexts, such as emerging viral infections or resistant cancer subtypes.

Mechanism of Action of DiscoveryProbe™ FDA-approved Drug Library

The DiscoveryProbe™ FDA-approved Drug Library encompasses compounds representing diverse mechanisms of action:

• Receptor agonists/antagonists: Target G protein-coupled receptors (GPCRs), nuclear receptors, and ion channels to modulate cellular responses.
• Enzyme inhibitors: Block catalytic activities of kinases, proteases, and polymerases, influencing signaling and metabolic pathways.
• Ion channel modulators: Alter neuronal signaling, cardiac function, and muscle contractility by regulating ion fluxes.
• Signal pathway regulators: Interfere with key nodes in pathways such as PI3K/AKT/mTOR, MAPK, and Wnt/β-catenin.

Representative compounds include doxorubicin (topoisomerase II inhibitor), metformin (AMPK activator), and atorvastatin (HMG-CoA reductase inhibitor). The inclusion of such well-characterized agents facilitates the elucidation of cellular pathways and the identification of druggable targets in complex disease models [Internal: High-Content Screening].

Evidence & Benchmarks

• High-throughput screening of 6,644 small molecules, including FDA-approved drugs, led to the identification of four selective hepatitis delta virus (HDV) ribozyme inhibitors, with 8-azaguanine being the most potent (Tseligka et al., 2023, https://doi.org/10.1016/j.jhepr.2022.100652).
• Among HDV-inhibiting molecules, three were histone deacetylase (HDAC) inhibitors, illustrating the library's coverage of epigenetic modulators (Tseligka et al., 2023, https://doi.org/10.1016/j.jhepr.2022.100652).
• Drug repositioning strategies utilizing FDA-approved compound libraries have resulted in accelerated identification of antiviral and anticancer drug candidates (Zhang et al., 2020, https://doi.org/10.1038/s41573-020-0072-6).
• Compounds in pre-dissolved 10 mM DMSO format remain chemically stable for at least 12 months at -20°C and 24 months at -80°C, ensuring reproducibility (ApexBio Tech Specs, https://www.apexbt.com/discoveryprobetm-fda-approved-drug-library.html).

Applications, Limits & Misconceptions

The DiscoveryProbe™ FDA-approved Drug Library is applied in:

• Drug repositioning screening: Identifying new indications for existing drugs, expediting clinical translation.
• Pharmacological target identification: Mapping compound effects to specific molecular targets in disease-relevant models.
• Cancer and neurodegenerative research: Screening for cytotoxicity, neuroprotection, or pathway modulation.
• Signal pathway regulation studies: Dissecting the contribution of signaling cascades to cell fate and disease progression.
• Enzyme inhibitor screening: Rapidly evaluating compound panels against defined enzymatic activities.

Compared to the overview in this internal article, which emphasizes time-dependent responses, this article details mechanistic and workflow considerations for target identification and screening limits.

Common Pitfalls or Misconceptions

• The library does not include investigational or preclinical compounds not yet approved by a major agency.
• It is not suitable for direct in vivo administration without proper dilution and formulation, as compounds are provided in DMSO.
• Screening results depend on cell type, assay conditions, and compound solubility; false negatives may occur in non-permissive models.
• The collection is not exhaustive of all global approved drugs; it focuses on those with robust clinical and regulatory documentation.
• Batch-to-batch consistency is high, but researchers must account for possible compound degradation if storage guidelines are not strictly followed.

Workflow Integration & Parameters

The DiscoveryProbe™ FDA-approved Drug Library is optimized for HTS and HCS workflows. Compounds are arrayed in 96-well microplates, deep well plates, or 2D barcoded screw-top tubes, all compatible with automated liquid handlers. Each well contains a 10 mM solution in DMSO, with a typical working concentration of 1–10 µM after dilution. Shipping occurs on blue ice for evaluation samples and at room temperature or on blue ice for larger orders, per customer request. The solutions are stable for 12 months at -20°C and up to 24 months at -80°C [ApexBio].

Integration into workflows requires calibration of assay volumes, cell densities, and detection methods (e.g., luminescence, fluorescence, imaging). Z' factors above 0.4 are recommended for assay validity, as in recent HDV ribozyme inhibitor screens (Tseligka et al., 2023). For a comparison of how this library performs in translational workflows, see this internal resource, which focuses on rapid, reproducible HTS in oncology and infectious diseases.

Conclusion & Outlook

The DiscoveryProbe™ FDA-approved Drug Library (L1021) is a rigorously curated platform for high-throughput drug screening, drug repositioning, and pharmacological target identification. Its coverage of FDA, EMA, HMA, CFDA, and PMDA-approved molecules, combined with stability and ready-to-screen formats, enables diverse research applications. Ongoing developments in phenotypic screening, disease modeling, and integrative omics will further enhance the utility of this resource for new therapeutic discoveries. For detailed specifications and ordering, visit the DiscoveryProbe™ FDA-approved Drug Library product page.